Rephonic
Artwork for The Readout Loud

The Readout Loud

STAT
FDA
Eli Lilly
Novo Nordisk
Biotechnology
Pfizer
Gene Therapy
Covid-19
Duchenne Muscular Dystrophy
Vertex Pharmaceuticals
CRISPR
Drug Pricing
RFK Jr.
Sarepta Therapeutics
Moderna
Biotech
Biotech Industry
Obesity
Astrazeneca
Obesity Drugs
Glp-1

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

PublishesWeeklyEpisodes427Founded9 years ago
Number of ListenersCategory
Business

Listen to this Podcast

Artwork for The Readout Loud

Latest Episodes

On this week’s episode of "The Readout LOUD": The FDA is once again searching for a new leader, a closely tracked lung cancer drug suffers an FDA rejection, and China’s largest drugmakers ranked.

We invite you to listen to this pre-Thanksgiving epis... more

On this week’s episode of "The Readout LOUD": the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug research. Plus, drug safety concerns weigh on some of the biggest companies in t... more

How will the midterm results affect drug pricing policy? What is the fate of the Food and Drug Administration? And why are women traveling to fertility clinics abroad?

On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on... more

What is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna's mRNA cancer vaccine? And what are the next big advances in oncology?

On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on our col... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Raising Health
Raising HealthAndreessen Horowitz, a16z Bio + Health
The Journal.
The Journal.The Wall Street Journal & Spotify Studios

Recent Guests

Matthew Herper
Senior medical writer at STAT
STAT
Episode: 421: The future of heart drug research in the wake of study setbacks
Daniel Payne
STAT Washington correspondent covering health and medicine
STAT
Episode: 420: Democrats’ midterm victory, and a questionable fertility procedure
Megan Molteni
STAT reporter who investigated clinics marketing mitochondrial replacement for fertility
STAT
Episode: 420: Democrats’ midterm victory, and a questionable fertility procedure
Andrew Joseph
STAT journalist covering biotech and cancer research
STAT
Episode: 419: Assessing Merck and Moderna's mRNA cancer vaccine
Rick Burke
STAT executive editor who hired Helen Branswell
STAT
Episode: 418: Remembering STAT’s Helen Branswell
Brenda Branswell
Helen Branswell's younger sister
Episode: 418: Remembering STAT’s Helen Branswell
Sarah Todd
STAT reporter covering longevity medicine and health care
STAT
Episode: 417: Hospitals' next lucrative bet — longevity clinics
Anil Oza
Reporter covering NIH policy and funding
STAT
Episode: 416: NIH funding uncertainty thwarts U.S. researchers
Heather Pierce
Senior Director of Science Policy
Association of American Medical Colleges
Episode: 416: NIH funding uncertainty thwarts U.S. researchers

Hosts

Allison DeAngelis
Biotech journalist covering biotechnology and health care
Adam Feuerstein
Journalist covering biotechnology
Elaine Chen
Journalist covering health care

Reviews

4.7 out of 5 stars from 601 ratings
  • Constructive Feedback on Episode 398

    Hey STAT Team - As a long time reader and biotech CEO, I wanted to pass on hopefully constructive feedback on your show in general and this specific episode. I really enjoyed hearing the inside scoop from Bryan Roberts on Kelonia and the Lilly deal. That was great. Please do more of that! In the constructive feedback category, the one thing that I would caution you on, both in this episode and others, is the trivial nature (joking, in fact) in how you handle very, very tough times for these comp... more

    Apple Podcasts
    3
    DP75007
    United States7 months ago
  • David Olson

    Thoughtful and concise discussion about drug development processes. I found this illuminating

    and hopeful

    Apple Podcasts
    5
    Auldkirk
    United Kingdoma year ago
  • Really informative and relevant

    Great coverage by the three hosts.

    Only area of improvement is if the audio editor can adjust the volume for all speakers to be equal because for some reason Elaine’s mic tends to be the loudest and I have to keep adjusting the volume for each speaker.

    Apple Podcasts
    4
    orange03$592
    United Statesa year ago
  • Great pod!

    This is a great overview of the biopharm space with an engaging and fun style. I also like the unrelated chat amongst the team, particularly as a fellow fan of the Great British Bake Off, given this is an industry that can often take itself very seriously!

    Apple Podcasts
    5
    123etcetc
    United Kingdoma year ago
  • Please reboot the old quality bar

    This podcast was a gold mine a few years back. Really miss that run you had. Adam is good but even he was better back when surrounded with higher caliber cohosts.

    Apple Podcasts
    3
    freedomtochoose
    United Statesa year ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Listeners value the concise, informative coverage as a way to keep up with biotech and pharmaceutical news.
A few listeners flag uneven microphone levels, filler words and a jarring theme song as production or delivery issues.
Many praise the hosts' industry knowledge, engaging style and ability to make complex developments accessible.
A recurring criticism is that political coverage can feel one-sided, which some listeners say affects their trust in the analysis.
Some listeners find the informal banter and jokes entertaining, while others say in-jokes or flippant treatment of difficult industry events can distract.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#150
Argentina/Business
Apple Podcasts
#185
Singapore/Business
Apple Podcasts
#249
Russia/Business

Talking Points

Recent interactions between the hosts and their guests.

421: The future of heart drug research in the wake of study setbacks
Q: Do you think the setbacks reported at the AHA meeting are going to cause biotech and pharma companies to cut back on the development of new heart medicines?
Herper says companies have already reduced cardiovascular drug development and the failures are unlikely to accelerate it. The field requires substantial capital and long, expensive trials, making it difficult for smaller biotech companies to advance new medicines.
421: The future of heart drug research in the wake of study setbacks
Q: What does it mean that the drugs targeted their intended biology but did not produce cardiovascular or survival benefit?
Herper says genetic evidence can show that a biological target is associated with disease risk, but it cannot guarantee that changing the target with a drug will improve patient outcomes. The drugs may not have affected the targets sufficiently, and genetic validation is not proof of clinical efficacy.
420: Democrats’ midterm victory, and a questionable fertility procedure
Q: So to start off, what is MRT and why is this procedure so controversial?
Megan Molteni explains that mitochondrial replacement techniques combine nuclear DNA from the intended parents with donor mitochondria. The procedure is controversial because its long-term health effects are not well understood.
420: Democrats’ midterm victory, and a questionable fertility procedure
Q: Now that Democrats have the majority in the Senate and the House, do we expect any more movement on drug pricing?
Daniel Payne expects movement, noting that Democrats are more open to government intervention in pricing, though turning policy goals into legislation and funding them will be difficult.
419: Assessing Merck and Moderna's mRNA cancer vaccine
Q: Why did Moderna's stock sell off when the cancer vaccine data were released?
The stock had gained substantial market value after the earlier positive announcement, so some investors may have sold on the news when detailed results emerged. The decline reflected market expectations rather than evidence that the results were poor.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The Readout Loud

What is The Readout Loud about and what kind of topics does it cover?

Weekly conversations make biotech and health care news accessible through a mix of reporter-led roundups, deeper investigations and expert interviews. Recurring hosts Allison DeAngelis, Adam Feuerstein and Elaine Chen bring a journalist's perspective to drug development, clinical trial results, FDA decisions, company strategy and the policies shaping biomedical research. Guests include clinicians, researchers, industry executives, patient advocates and policy specialists, alongside colleagues reporting on the stories under discussion.

Coverage ranges from emerging therapies and biotech market moves to health care costs, research funding and public trust in science. The format combines detailed analysis with informal host conversation, and ... more

Where can I find podcast stats for The Readout Loud?

Rephonic provides a wide range of podcast stats for The Readout Loud. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The Readout Loud and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The Readout Loud get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for The Readout Loud, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The Readout Loud?

Rephonic provides comprehensive predictive audience data for The Readout Loud, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The Readout Loud have?

To see how many followers or subscribers The Readout Loud has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The Readout Loud?

These podcasts share a similar audience with The Readout Loud:

1. BioCentury This Week
2. Biotech Hangout
3. The Long Run with Luke Timmerman
4. Raising Health
5. The Journal.

How many episodes of The Readout Loud are there?

The Readout Loud launched 9 years ago and published 427 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The Readout Loud?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The Readout Loud?

Rephonic pulls ratings and reviews for The Readout Loud from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The Readout Loud?

Rephonic provides full transcripts for episodes of The Readout Loud. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The Readout Loud?

Recent guests on The Readout Loud include:

1. Matthew Herper
2. Daniel Payne
3. Megan Molteni
4. Andrew Joseph
5. Rick Burke
6. Brenda Branswell
7. Sarah Todd
8. Anil Oza

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days